Poor tumor targeting, strong toxic side effects, and high drug resistance remain clinical challenges for conventional chemotherapy. Here, it is reported that drug-cocktail core@shell nanocarriers are developed for the codelivery of lipophilic irinotecan (ITC) ... ...

请注册登录后继续浏览